Sudarshan Pharma Industries Ltd · BSE:SUDARSHAN
Sudarshan Pharma Industries — Investor Presentation (September 2023)
33 slides from Sudarshan Pharma Industries's investor presentation, September 2023
Slide 1: Sudarshan Pharma Industries Limited Investor Presentation September 2023
Sudarshan Pharma Industries Limited INVESTOR PRESENTATION September 2023
Slide 2: Disclaimer
Disclaimer Investor Presentation 2
Slide 3: Table of Content
Table of Content 1 2 3 31 2 3 ABOUT US BUSINESS INDUSTRY OVERVIEW OVERVIEW 4 1 5 4 5 WAY ANNUAL FORWARD HIGHLIGHTS Investor Presentation 3
Slide 4: About Us
ABOUT US
Slide 5: About Us
About Us A Specialty Chemicals & Pharmaceutical Manufacturing Company DIVERSIFIED GLOBAL ESTEEMED 15+ YEARS PRODUCTS REACH CLIENTS Founded in 2008, The Company specializes The company has marked Key clients in Sudarshan Pharma in host of products from its presence in India and pharmaceutical Industr
Slide 6: Lead Management
Lead Management Mr. Hemal V. Mehta Mr. Sachin V. Mehta Chairman & Management Director Joint Managing Director Experience of 15+ years in Sourcing and Supply of Plays a crucial role in sourcing of Specialty Chemicals, Specialty Chemicals, Intermediates, API and Bulk Drugs. Intermediates & Basic Solve
Slide 7: Board Of Directors
Board Of Directors Umesh Luthra Jaya Sharma Rushabh Patil Independent Director Independent Director Independent Director Result oriented Biotech Professional with Registered as an Independent Director with Adv. Rushabh Prashant Patil is a Practicing General Management knowledge having the databank o
Slide 8: Milestones
Milestones Incorporated in 2008, the company has achieved new heights every year since 2011. 2011-12 2015-16 2019-20 2023 • Generic formulations for • Over 5,000 medical • Launch Hart Kit Loading • Developing new products institution supply, NGO’s practitioners associated with Dose And Hart Kit-4. l
Slide 9: Business Overview
BUSINESS OVERVIEW
Slide 10: Business Model
Business Model Sudarshan Pharma Industries Ltd Domestic Market International Market Speciality Chemical Products Direct Marketing API/Formulations/ Other Pharma Products In-House Sales & Speciality API/Formulation Contract Institutional Marketing - VIMAC Chemicals Trading Trading Manufacturing Marke
Slide 11: Key Business Verticals
Key Business Verticals 1. 2. Ethical marketing of branded Contract manufacturing and and unbranded generics in the supply of pharmaceutical domestic pharmaceuticals formulations and medicines for market through our own well-known Pharmaceutical distribution logistics network Companies in India and a
Slide 12: Global Reach
Global Reach Presence Total Export Revenue (INR Mn) 5 States 57.8 Mn ❑ Office - Mumbai, Maharashtra ❑ Plants - Maharashtra - Palghar, Wada Exporting Countries ➢ Bangladesh ➢ Ghana ➢ Qatar ➢ Oman ➢ Somalia ➢ Nepal ➢ Saudi Arabia ➢ South Africa ➢ Sri Lanka ➢ Jordan ➢ UAE Investor Presentation 12
Slide 13: Our Products
Our Products SPECIALTY CHEMICALS ETHICAL PHARMA DIVISION 56 out of 96 products are Registered under ―”R” Trade ▪ Acetonitrile Mark. ▪ Tetrahydrofuran (THF) ▪ SPIL has adopted Novel drug Delivery System for Love Bird “R” Brand. It’s a mouth dissolving strip and has 5 ▪ 1,4-Dioxane products under this
Slide 14: Key Problem Area
Key Problem Area Dependence on China for Import of key APIs Top 5 categories of imports occupy 80% of the share of API imports India imports ~70% of Intermediate Also, the pandemic which started Imports from Categories required for APIs (Active spreading in the previous year China (%) Pharmaceutical
Slide 15: Addressing the Problem
Addressing the Problem The central government has earmarked ~Rs 100 billion for the bulk drug industry, including Rs 30 billion for the promotion of bulk drug parks (for the next five years) and Rs 69.4 billion for a production-linked incentive scheme for the promotion of domestic manufacturing of c
Slide 16: Business Strengths
Business Strengths Established Manufacturing & supply chain for Belief in cost plus formula Chemical, Pharma & and after sales services. formulation. Quality manufacturing Experienced Management facility with Hi-tech team with a dedicated Machines duly approved workforce. by FDA & other agencies. F&
Slide 17: Clientele
Clientele SPECIALTY CHEMICALS PHARMACEUTICAL FORMULATIONS Investor Presentation 17
Slide 18: Industry Overview
INDUSTRY OVERVIEW PHARMA INDUSTRY strong in INDIA although highly dependent on CHINA
Slide 19: India - Overview
India - Overview A significant and rising player in the Global Pharmaceutical industry US$ 42 bn 40% 20% India's pharmaceutical Of generic demand in the US, Of the worldwide supply by market in 2021. It is likely to and 25% of all medicine in the volume and supplying about reach US$ 65 billion by 20
Slide 20: India - a strong exporter of pharma products globally
INDIA- a strong exporter of pharma products Globally ✓ India’s drugs and pharmaceutical exports stood at US$ 24.44 billion in FY21. ✓ India is the 12th largest exporter of medical goods in the world. ✓ The country’s pharmaceutical sector contributes 6.6% to the total merchandise exports. ✓ Indian dr
Slide 21: Competitive Landscape
Competitive Landscape Formulation Industry Owing to high profit margins majority of the company’s competitors are in the formulation export Investor Presentation 21
Slide 22: Way Forward & Key Developments
WAY FORWARD & KEY DEVELOPMENTS SUDARSHAN PHARMA On the cusp of Transformation
Slide 23: Way Forward
Way Forward READY TO TAKE OFF WITH NEW Expansion of Sales PRODUCTS & MARKETS footprint in the Pharma formulations and medicine in the Domestic and Export markets Focus on Pharma formulations and branded generic medicines through the launch of new products in the Gyeny, Chronic diseases, Gastrointest
Slide 24: Key Developments (1/4)
Key Developments (1/4) 1) Investments under the Government PLI Programme The company had received an approval under the PLI scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSM), Drug Intermediates (Dis) and Active Pharmaceutical Ingredients (APIs) in India. Unit 1:
Slide 25: Key Developments (2/4)
Key Developments (2/4) 2) Maharashtra Govt. Subsidies for new project • Pharma Items Manufacturing Project by Sudarshan Group at Mahad MIDC (C Zone) has following subsidy benefits from State Government of Maharashtra, Industries Department , Under PSI‐2019 scheme. • Mahad is Under C Zone hence benef
Slide 26: Key Developments (3/4)
Key Developments (3/4) 3) Updates on the new manufacturing Unit 2 • The company has recently setup its Unit 2 at Palghar, Maharashtra. • Key activities at this unit will include from testing of raw materials to dispensing raw materials for formulations, to batch manufacturing as per approved standar
Slide 27: Key Developments (4/4)
Key Developments (4/4) 4) Partnership for distribution of Key Products in India Product 1: Product 2: Product 3: APIs/Intermediates in India Sucralose Beta • Hydroxypropyl Methyl Cellulose Cyclodextrin 5 Years (HPMC) Distribution Agreement • Low‐Substituted Hydroxypropyl USD USD USD USD Cellulose (L
Slide 28: Acquisition - Ratna Lifesciences Pvt Ltd
Acquisition - Ratna Lifesciences Pvt Ltd 100% Rs 55 Million 30 August 2023 Wholly Owned Subsidiary Paid-up Share capital Payable in various tranches Acquisition Completion date Of Sudarshan Pharma Industries Ltd. About the company: Existing Products: Capacity: M/s Ratna Lifesciences Private Ltd was
Slide 29: Annual Highlights
Annual Highlights
Slide 30: Annual Income Statement
Annual Income Statement (Consolidated) Particulars (INR Mn) FY21 FY22 FY23 Net Sales 1,933.5 3,570.9 4,613.3 Total Revenue from Operations 1,933.5 3,570.9 4,613.3 Total Expenditure 1,861.9 3,461.8 4,466.4 EBITDA 71.6 109.1 146.9 EBITDA Margin (%) 3.7% 3.1% 3.2% Depreciation 7.4 8.7 9.1 PBIT 64.2 100
Slide 31: Annual Balance Sheet
Annual Balance Sheet (Consolidated) Particulars (INR Mn) FY23 FY22 Particulars (INR Mn) FY23 FY22 Equity and Liabilities Assets Shareholder's Fund Non-Current Assets Share Capital 240.7 97.5 Property, Plant, Equipment & Intangible Assets Reserves & Surplus 769.1 200.3 - Property, Plant & Equipment 1
Slide 32: Key Financial Charts
Key Financial Charts (Consolidated) Revenue from Operations (INR Mn) EBITDA (INR Mn) 5500 200 4500 150 3500 100 2500 4613.3 146.9 1500 3570.9 50 109.1 1933.5 71.6 500 0 -500 FY21 FY22 FY23 FY21 FY22 FY23 Profit After Tax (INR Mn) Earnings Per Share (INR) 100 10 80 8 60 6 4 40 70.4 5.46 * 5.48 * 52.5
Slide 33: Thank You
THANK YOU Sudarshan Pharma Industries Ltd Ms. Ishita Ashok Samani, Company Secretary & Compliance Officer Tel: +91-22-4222 1123 | Email: compliance@sudarshanpharma.com www.sudarshanpharma.com
Sudarshan Pharma Industries — Investor Presentation (September 2023) on 6ix